{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:05:39Z","timestamp":1790607939424,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL128411"],"award-info":[{"award-number":["R01 HL128411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ymthe.2022.08.024","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T21:01:56Z","timestamp":1662411716000},"page":"3106-3117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-5241","authenticated-orcid":false,"given":"Isabella","family":"Hetherington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-0377","authenticated-orcid":false,"given":"Hana","family":"Totary-Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.08.024_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2022.08.024_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/CIRCULATIONAHA.105.593418","article-title":"Aortic atherosclerotic disease and stroke","volume":"114","author":"Kronzon","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib5","doi-asserted-by":"crossref","first-page":"e111785","DOI":"10.1371\/journal.pone.0111785","article-title":"Biomechanics and inflammation in atherosclerotic plaque erosion and plaque rupture: implications for cardiovascular events in women","volume":"9","author":"Campbell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.08.024_bib6","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrcardio.2012.64","article-title":"The importance of the endothelium in atherothrombosis and coronary stenting","volume":"9","author":"Otsuka","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/01.ATV.20.3.728","article-title":"Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation","volume":"20","author":"Perrault","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/hr.2012.138","article-title":"Endothelial dysfunction and hypertension in aging","volume":"35","author":"Higashi","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/01.CIR.94.6.1276","article-title":"Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus","volume":"94","author":"M\u00e4kimattila","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib12","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1152\/ajpendo.2000.279.1.E11","article-title":"Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression","volume":"279","author":"Ding","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2022.08.024_bib13","doi-asserted-by":"crossref","first-page":"102346","DOI":"10.1016\/j.nano.2020.102346","article-title":"Nanoparticles target intimal macrophages in atherosclerotic lesions","volume":"32","author":"Dhanasekara","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ymthe.2022.08.024_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157011","article-title":"Through the layers: how macrophages drive atherosclerosis across the vessel wall","volume":"132","author":"Susser","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.024_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.smim.2015.03.013","article-title":"Atherosclerosis - a matter of unresolved inflammation","volume":"27","author":"Viola","year":"2015","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib16","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1172\/JCI82719","article-title":"Endothelial-to-mesenchymal transition drives atherosclerosis progression","volume":"125","author":"Chen","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.024_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41569-018-0023-y","article-title":"Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases","volume":"15","author":"Li","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib18","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/CIRCULATIONAHA.113.005015","article-title":"Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis","volume":"129","author":"Allahverdian","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib22","doi-asserted-by":"crossref","first-page":"e012322","DOI":"10.1161\/JAHA.119.012322","article-title":"Clinical and laboratory predictors for plaque erosion in patients with acute coronary syndromes","volume":"8","author":"Yamamoto","year":"2019","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2022.08.024_bib23","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.CIR.93.7.1354","article-title":"Coronary plaque erosion without rupture into a lipid core","volume":"93","author":"Farb","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2105\/AJPH.41.3.279","article-title":"Epidemiological approaches to heart disease: the Framingham study","volume":"41","author":"Dawber","year":"1951","journal-title":"Am. J. Public Health Nations Health"},{"key":"10.1016\/j.ymthe.2022.08.024_bib25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJMp2033115","article-title":"Conquering atherosclerotic cardiovascular disease - 50 years of progress","volume":"384","author":"Gibbons","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib26","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib27","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1001\/jama.1987.03390160062027","article-title":"Cholesterol and mortality. 30 years of follow-up from the Framingham study","volume":"257","author":"Anderson","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2022.08.024_bib28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib29","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2022.08.024_bib30","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2022.08.024_bib31","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol. Sin."},{"key":"10.1016\/j.ymthe.2022.08.024_bib32","first-page":"P1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib34","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.4049\/jimmunol.176.12.7657","article-title":"Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease","volume":"176","author":"Morimoto","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1476-5381.2011.01597.x","article-title":"Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?","volume":"165","author":"Balakumar","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib36","doi-asserted-by":"crossref","first-page":"101088","DOI":"10.1016\/j.redox.2018.101088","article-title":"Statin treatment, oxidative stress and inflammation in a Danish population","volume":"21","author":"Sorensen","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.ymthe.2022.08.024_bib39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.ymthe.2022.08.024_bib41","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMe0908841","article-title":"Statin therapy with ezetimibe or niacin in high-risk patients","volume":"361","author":"Kastelein","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2022.08.024_bib43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib44","doi-asserted-by":"crossref","first-page":"927352","DOI":"10.6064\/2012\/927352","article-title":"Proprotein convertase subtilisin\/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases","volume":"2012","author":"Ferri","year":"2012","journal-title":"Scientifica"},{"key":"10.1016\/j.ymthe.2022.08.024_bib45","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib46","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-Label Study of Long-Term Evaluation against LDLCI. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_20_20","article-title":"PCSK9 monoclonal antibodies: an overview","volume":"21","author":"Kaddoura","year":"2020","journal-title":"Heart Views"},{"key":"10.1016\/j.ymthe.2022.08.024_bib48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib49","author":"Administration"},{"key":"10.1016\/j.ymthe.2022.08.024_bib50","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Collaboration","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib51","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/archinte.1996.00440160064009","article-title":"Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications","volume":"156","author":"Chobanian","year":"1996","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib52","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.ymthe.2022.08.024_bib54","series-title":"Beta Blockers","author":"Farzam","year":"2021"},{"key":"10.1016\/j.ymthe.2022.08.024_bib55","series-title":"Angiotensin II Receptor Blockers (ARB)","author":"Hill","year":"2022"},{"key":"10.1016\/j.ymthe.2022.08.024_bib56","doi-asserted-by":"crossref","first-page":"e00644","DOI":"10.1002\/prp2.644","article-title":"Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis","volume":"8","author":"Buawangpong","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ymthe.2022.08.024_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"Brown","year":"2018","journal-title":"Pregnancy Hypertens."},{"key":"10.1016\/j.ymthe.2022.08.024_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/HYPERTENSIONAHA.117.09110","article-title":"Pregnancy outcome after first trimester use of methyldopa: a prospective cohort study","volume":"70","author":"Hoeltzenbein","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2022.08.024_bib59","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1161\/HYPERTENSIONAHA.117.09972","article-title":"Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial","volume":"70","author":"Webster","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2022.08.024_bib60","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J.\u00a0Hypertens."},{"key":"10.1016\/j.ymthe.2022.08.024_bib61","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib62","first-page":"308","article-title":"Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged >\/= 80 years","volume":"14","author":"Liang","year":"2017","journal-title":"J.\u00a0Geriatr. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib63","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","article-title":"Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort","volume":"63","author":"Calhoun","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2022.08.024_bib64","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/HYPERTENSIONAHA.116.06587","article-title":"Refractory hypertension: a novel phenotype of antihypertensive treatment failure","volume":"67","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ymthe.2022.08.024_bib65","doi-asserted-by":"crossref","first-page":"e007365","DOI":"10.1161\/JAHA.117.007365","article-title":"Prevalence and clinical characteristics of refractory hypertension","volume":"6","author":"Armario","year":"2017","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2022.08.024_bib66","author":"Organization"},{"key":"10.1016\/j.ymthe.2022.08.024_bib67","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/nature08933","article-title":"Genetics, pathogenesis and clinical interventions in type 1 diabetes","volume":"464","author":"Bluestone","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib68","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib69","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2022.08.024_bib70","doi-asserted-by":"crossref","first-page":"807548","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib71","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib72","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","article-title":"Diabetes mellitus and cardiovascular disease","volume":"39","author":"Schmidt","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-147-3-200708070-00167","article-title":"Mortality trends in men and women with diabetes, 1971 to 2000","volume":"147","author":"Gregg","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib75","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib76","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2337\/dc10-1170","article-title":"All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny county type 1 diabetes registry","volume":"33","author":"Secrest","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ymthe.2022.08.024_bib77","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib78","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"Farkouh","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","article-title":"Transluminal dilatation of coronary-artery stenosis","volume":"1","author":"Gruntzig","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib80","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM199404073301407","article-title":"Percutaneous transluminal coronary angioplasty","volume":"330","author":"Landau","year":"1994","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jpm8040033","article-title":"40 years of percutaneous coronary intervention: history and future directions","volume":"8","author":"Canfield","year":"2018","journal-title":"J.\u00a0Pers Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib82","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","article-title":"Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery","volume":"354","author":"Schillinger","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib83","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib84","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","article-title":"Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden","volume":"356","author":"Lagerqvist","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib85","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2011.10.909","article-title":"In-stent neoatherosclerosis: a final common pathway of late stent failure","volume":"59","author":"Park","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib86","first-page":"639","article-title":"Stent thrombosis after percutaneous coronary intervention: from bare-metal to the last generation of drug-eluting stents","volume":"38","author":"Polimeni","year":"2020","journal-title":"Cardiol. Clin."},{"key":"10.1016\/j.ymthe.2022.08.024_bib87","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa1505215","article-title":"Long-term results of stenting versus endarterectomy for carotid-artery stenosis","volume":"374","author":"Brott","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib88","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12928-021-00754-x","article-title":"Drug-eluting stent thrombosis: current and future perspectives","volume":"36","author":"Kuramitsu","year":"2021","journal-title":"Cardiovasc. Interv. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib89","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18, 334 patients","volume":"6","author":"Tada","year":"2013","journal-title":"JACC. Cardiovasc. Interv."},{"key":"10.1016\/j.ymthe.2022.08.024_bib90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/14779072.2018.1523718","article-title":"Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib91","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2796.2008.01959.x","article-title":"Introduction: atherosclerosis as inflammation: a controversial concept becomes accepted","volume":"263","author":"Hansson","year":"2008","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib92","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2007.02.052","article-title":"C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus","volume":"49","author":"Ridker","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib93","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis - from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.08.024_bib95","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","article-title":"Novel antiatherosclerotic therapies","volume":"39","author":"Libby","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib96","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib97","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib98","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1161\/CIRCRESAHA.114.302699","article-title":"Inflammation and its resolution as determinants of acute coronary syndromes","volume":"114","author":"Libby","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib99","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4049\/jimmunol.1601563","article-title":"Oxidized low-density lipoprotein immune complex priming of the Nlrp3 inflammasome involves TLR and FcgammaR cooperation and is dependent on CARD9","volume":"198","author":"Rhoads","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCULATIONAHA.113.002714","article-title":"Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility","volume":"128","author":"Xiao","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib101","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCRESAHA.115.304437","article-title":"Moderate hypoxia potentiates interleukin-1beta production in activated human macrophages","volume":"115","author":"Folco","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib102","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1073\/pnas.1620458114","article-title":"Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia","volume":"114","author":"Gupta","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.08.024_bib103","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/bloodadvances.2020003377","article-title":"Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice","volume":"5","author":"Campos","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2022.08.024_bib104","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.08.024_bib105","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.15252\/embj.201694696","article-title":"GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death","volume":"35","author":"Sborgi","year":"2016","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2022.08.024_bib106","doi-asserted-by":"crossref","first-page":"e012219","DOI":"10.1161\/JAHA.119.012219","article-title":"Novel insights into the NLRP 3 inflammasome in atherosclerosis","volume":"8","author":"Jin","year":"2019","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.ymthe.2022.08.024_bib107","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.ymthe.2022.08.024_bib109","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jacc.2021.06.037","article-title":"Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome","volume":"78","author":"Opstal","year":"2021","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2 Pt 2","key":"10.1016\/j.ymthe.2022.08.024_bib111","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC. Cardiovasc. Imaging"},{"key":"10.1016\/j.ymthe.2022.08.024_bib112","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib113","first-page":"9883352","article-title":"Current management guidelines on hyperlipidemia: the silent killer","volume":"2021","author":"Su","year":"2021","journal-title":"J.\u00a0Lipids"},{"key":"10.1016\/j.ymthe.2022.08.024_bib114","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib115","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.08.024_bib116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fcvm.2017.00086","article-title":"Mechanisms and consequences of defective efferocytosis in atherosclerosis","volume":"4","author":"Yurdagul","year":"2017","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib117","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/CIRCULATIONAHA.116.025684","article-title":"The role of efferocytosis in atherosclerosis","volume":"135","author":"Kojima","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib118","doi-asserted-by":"crossref","first-page":"4749135","DOI":"10.1155\/2020\/4749135","article-title":"Recent advancements in CD47 signal transduction pathways involved in vascular diseases","volume":"2020","author":"Dou","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ymthe.2022.08.024_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib120","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41565-019-0619-3","article-title":"Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis","volume":"15","author":"Flores","year":"2020","journal-title":"Nat. Nanotechnol"},{"key":"10.1016\/j.ymthe.2022.08.024_bib121","doi-asserted-by":"crossref","first-page":"275ra20","DOI":"10.1126\/scitranslmed.aaa1065","article-title":"Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice","volume":"7","author":"Fredman","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib122","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/emmm.201201374","article-title":"Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype","volume":"4","author":"Cardilo-Reis","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149651","article-title":"Resolving monocytes generated through TRAM deletion attenuate atherosclerosis","volume":"6","author":"Geng","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.08.024_bib124","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib125","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/CIRCRESAHA.109.199570","article-title":"Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob\/ob mice and reversal by a fish oil diet","volume":"105","author":"Li","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib126","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/ATVBAHA.118.311569","article-title":"Nanoparticle therapy for vascular diseases","volume":"39","author":"Flores","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib127","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.08.024_bib129","first-page":"100214","article-title":"Nanotechnology for cardiovascular diseases","volume":"3","author":"Hu","year":"2022","journal-title":"Innovation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: clinical developments in liposomal applications","volume":"10","author":"Beltr\u00e1n-Gracia","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib131","article-title":"Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib132","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/bc500517k","article-title":"HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages","volume":"26","author":"Sanchez-Gaytan","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2022.08.024_bib133","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/nl1041947","article-title":"Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery","volume":"11","author":"McMahon","year":"2011","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2022.08.024_bib134","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biomaterials.2010.08.078","article-title":"The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis","volume":"32","author":"Skajaa","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2022.08.024_bib135","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1021\/nl801958b","article-title":"Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform","volume":"8","author":"Cormode","year":"2008","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2022.08.024_bib136","doi-asserted-by":"crossref","first-page":"17135","DOI":"10.1038\/srep17135","article-title":"Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI","volume":"5","author":"Tarin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.08.024_bib137","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.107.719765","article-title":"Noninvasive in\u00a0vivo imaging of monocyte trafficking to atherosclerotic lesions","volume":"117","author":"Kircher","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib138","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.107.741181","article-title":"Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis","volume":"117","author":"Nahrendorf","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0143","article-title":"Deformable microparticles for shuttling nanoparticles to the vascular wall","volume":"7","author":"Fish","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.08.024_bib140","first-page":"96","article-title":"Nano-medicine for thrombosis: a precise diagnosis and treatment strategy","volume":"12","author":"Su","year":"2020","journal-title":"Nanomicro. Lett."},{"key":"10.1016\/j.ymthe.2022.08.024_bib141","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1073\/pnas.1303377110","article-title":"Development and in\u00a0vivo efficacy of targeted polymeric inflammation-resolving nanoparticles","volume":"110","author":"Kamaly","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2022.08.024_bib142","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.111.244186","article-title":"Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium","volume":"32","author":"Serrano","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib143","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.106.646380","article-title":"Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis","volume":"114","author":"Nahrendorf","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib144","doi-asserted-by":"crossref","first-page":"1900172","DOI":"10.1002\/advs.201900172","article-title":"Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2022.08.024_bib145","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1038\/s41467-020-16439-7","article-title":"Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines","volume":"11","author":"Gao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.08.024_bib146","doi-asserted-by":"crossref","first-page":"a014035","DOI":"10.1101\/cshperspect.a014035","article-title":"Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine","volume":"5","author":"Chien","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2022.08.024_bib147","doi-asserted-by":"crossref","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib148","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/mt.2016.143","article-title":"Viral and synthetic RNA vector technologies and applications","volume":"24","author":"Schott","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib149","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib150","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2alpha-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.08.024_bib151","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.08.024_bib152","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib153","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","article-title":"Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1\u00a0week post-myocardial infarction in swine","volume":"9","author":"Carlsson","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.08.024_bib154","doi-asserted-by":"crossref","first-page":"17509","DOI":"10.1038\/s41598-018-35570-6","article-title":"Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing","volume":"8","author":"Sun","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.08.024_bib155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.08.024_bib156","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.08.024_bib157","first-page":"e564","article-title":"Late-breaking science abstracts and featured science abstracts from the American heart association's scientific sessions 2021 and late-breaking abstracts in resuscitation science from the resuscitation science symposium 2021","volume":"144","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2022.08.024_bib158","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/mp5006239","article-title":"Synthetic chemically modified mRNA-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction","volume":"12","author":"Huang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2022.08.024_bib159","doi-asserted-by":"crossref","first-page":"2004661","DOI":"10.1002\/advs.202004661","article-title":"Therapeutic delivery of pip4k2c-modified mRNA attenuates cardiac hypertrophy and fibrosis in the failing heart","volume":"8","author":"Magadum","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2022.08.024_bib160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.08.024_bib161","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In\u00a0vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.08.024_bib162","series-title":"Verve Therapeutics Doses First Human with an Investigational in\u00a0Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia","year":"2022"},{"key":"10.1016\/j.ymthe.2022.08.024_bib163","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ymthe.2021.01.032","article-title":"Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis","volume":"29","author":"Lockhart","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.08.024_bib164","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.omtn.2018.12.007","article-title":"Nucleotide modification alters MicroRNA-dependent silencing of MicroRNA switches","volume":"14","author":"Lockhart","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2022.08.024_bib165","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1172\/JCI76069","article-title":"A selective microRNA-based strategy inhibits restenosis while preserving endothelial function","volume":"124","author":"Santulli","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.08.024_bib166","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2022.08.024_bib167","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1126\/science.aaw0553","article-title":"Making precision medicine personal for cystic fibrosis","volume":"365","author":"Manfredi","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.08.024_bib168","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:06:59Z","timestamp":1761502019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622005536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":168,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1525001622005536"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}